<DOC>
	<DOCNO>NCT02352402</DOCNO>
	<brief_summary>In POPular CABG study investigate addition ticagrelor , drug inhibits blood platelet clot , treatment aspirin reduce rate saphenous vein graft occlusion assess coronary compute tomography angiography 1 year coronary artery bypass graft surgery .</brief_summary>
	<brief_title>The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery</brief_title>
	<detailed_description>Rationale : Acetylsalicylic acid ( ASA ) use prevent occlusion graft place coronary artery bypass graft surgery ( CABG ) reduce incidence atherothrombotic event follow-up . Graft occlusion occur predominantly saphenous vein graft ( SVGs ) result symptom chest pain , myocardial infarction ( MI ) even death . The anti-thrombotic effect ASA result inhibition generation thromboxane A2 ( TXA2 ) blood platelet . Despite ASA therapy , 6.8 % 26 % SVGs occlude first year CABG , mainly due thrombus formation . This might due fact ASA equally effective patient , indicate substantial amount patient still generate TXA2 show activate platelet , despite adequate ASA use . We hypothesize potent platelet inhibition addition ticagrelor standard ASA therapy could decrease rate SVG occlusion . Main objective : To investigate whether combination ticagrelor 90mg twice daily ASA 80mg daily superior ASA 80mg daily alone prevention SVG occlusion patient underwent CABG use one SVGs , assess coronary compute tomography angiography ( CCTA ) 1 year randomization . Study design : Randomized , double-blind , placebo-controlled , multicenter trial . Number patient : Approximately 790 patient enter study , total 720 patient randomize surgery . Study population : Patients undergo isolated CABG one SVGs . Informed consent procedure , screen sample size : We screen patient obtain informed consent CABG . After CABG patient give inform consent screen check patient fulfills inclusion criterion exclusion criterion . A total 720 patient receive randomize study medication CABG . Intervention : Patients randomly assign treatment 90mg ticagrelor match placebo twice daily addition standard treatment ASA duration 1 year . Patients prescribe 80mg ASA daily accord routine clinical practice . Graft patency assess CCTA 1 year randomization . Platelet function test perform surgery 3 day 1 year randomization . Thirty day one-year follow-up clinical event obtain patient screen ( electronic ) patient file , telephonic interview , study site visit possibly questionnaire .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>More 21 year age Planned coronary artery bypass grafting ( CABG ) use 1 saphenous vein graft Unable give inform consent life expectancy le 1 year Concomitant valve , aorta rhythm surgery session Inability undergo coronary compute tomography angiography , investigator 's opinion , instance due severe claustrophobia contrast allergy Use oral anticoagulant ( acenocoumarol , phenprocoumon , dabigatran , rivaroxaban , etc ) contraindication discontinuation medication expectation patient indication use drug surgery Placement drugeluting stent coronary cerebral artery within 6 month CABG placement baremetal stent coronary cerebral artery within 1 month CABG Use antiplatelet drug aspirin ( clopidogrel , prasugrel , ticagrelor , dipyridamol , etc . ) contraindication discontinuation medication CABG , accord treat physician investigator Women know pregnant , give birth within past 90 day breastfeed Premenopausal woman without adequate contraception Severe renal function impairment require dialysis Moderate severe hepatic impairment Active malignancy increase bleeding risk , investigator 's opinion Use strong inhibitor CYP3A4 ( e.g . ketaconazole , clarithromycin , nefazodone , ritonavir , atazanavir ) Clinically significant range value platelet count haemoglobin screening , investigator 's opinion Contraindication use ticagrelor aspirin ( i.e . history intracranial bleeding , high bleeding risk , previous allergic reaction ) , investigator 's opinion Previous inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>CABG</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Graft</keyword>
	<keyword>Patency</keyword>
</DOC>